Stimuli-responsive therapeutic metallodrugs
The success of platinum-based anticancer agents has motivated the exploration of novel
metal-based drugs for several decades, whereas problems such as drug-resistance and …
metal-based drugs for several decades, whereas problems such as drug-resistance and …
Structure–activity relationships for ruthenium and osmium anticancer agents–towards clinical development
SM Meier-Menches, C Gerner, W Berger… - Chemical Society …, 2018 - pubs.rsc.org
Anticancer metallodrugs based on ruthenium and osmium are among the most investigated
and advanced non-platinum metallodrugs. Inorganic drug discovery with these agents has …
and advanced non-platinum metallodrugs. Inorganic drug discovery with these agents has …
The development of RAPTA compounds for the treatment of tumors
Abstract Ruthenium (II)-arene RAPTA-type compounds have been extensively explored for
their medicinal properties. Herein a comprehensive review of this class of compounds is …
their medicinal properties. Herein a comprehensive review of this class of compounds is …
Organometallic anticancer compounds
The quest for alternative drugs to the well-known cisplatin and its derivatives, which are still
used in more than 50% of the treatment regimes for patients suffering from cancer, is highly …
used in more than 50% of the treatment regimes for patients suffering from cancer, is highly …
Advancement of metal compounds as therapeutic and diagnostic metallodrugs: Current frontiers and future perspectives
Coordination compounds on account of distinctive features of metal ions that include
variable oxidation states, diverse range of geometries and coordination numbers …
variable oxidation states, diverse range of geometries and coordination numbers …
Chemistry and reactivity of ruthenium (II) complexes: DNA/protein binding mode and anticancer activity are related to the complex structure
In this review we summarize our work on development of Ru complexes with potential
antitumor activity, which was performed over the last few years. In order to establish the …
antitumor activity, which was performed over the last few years. In order to establish the …
KP1019, a new redox‐active anticancer agent–Preclinical development and results of a clinical phase I study in tumor patients
CG Hartinger, MA Jakupec… - Chemistry & …, 2008 - Wiley Online Library
The promising drug candidate indazolium trans‐[tetrachlorobis (1H‐indazole) ruthenate
(III)](KP1019) is the second Ru‐based anticancer agent to enter clinical trials. In this review …
(III)](KP1019) is the second Ru‐based anticancer agent to enter clinical trials. In this review …
Bioorganometallic chemistry—from teaching paradigms to medicinal applications
In undergraduate level organometallic chemistry courses students are usually taught that
organometallic compounds are toxic and unstable in air and water. While this is true of many …
organometallic compounds are toxic and unstable in air and water. While this is true of many …
Arene ruthenium complexes as anticancer agents
G Süss-Fink - Dalton Transactions, 2010 - pubs.rsc.org
Neutral or cationic arene ruthenium complexes providing both hydrophilic as well as
hydrophobic properties due to the robustness of the ruthenium–arene unit hold a high …
hydrophobic properties due to the robustness of the ruthenium–arene unit hold a high …
Designing organometallic compounds for catalysis and therapy
Bioorganometallic chemistry is a rapidly develo** area of research. In recent years
organometallic compounds have provided a rich platform for the design of effective catalysts …
organometallic compounds have provided a rich platform for the design of effective catalysts …